Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease that mainly affects middle-aged women. Obeticholic acid (OCA), which was recently approved by the Food and Drug Administration for PBC treatment, has demonstrated positive effects on biochemical markers of liver function. Our objective was to evaluate the long-term clinical impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA. We developed a mathematical model to simulate the lifetime course of PBC patients treated with OCA1UDCA versus UDCA alone. Efficacy data were derived from the phase 3 PBC OCA International Study of Efficacy trial, and the natural history of PBC was informed by published clinical studies. Model outcomes were validated using the PBC Global Study. We found that in comparison with UDCA, OCA-UDCA could decrease the 15-year cumulative incidences of decompensated cirrhosis from 12.2% to 4.5%, hepatocellular carcinoma from 9.1% to 4.0%, liver transplants from 4.5% to 1.2%, and liver-related deaths from 16.2% to 5.7% and increase 15-year transplant-free survival from 61.1% to 72.9%. The lifetime cost of PBC treatment would increase from $63,000 to $902,000 (1,330% increment). The discounted quality-adjusted life years with UDCA and OCA1UDCA were 10.74 and 11.78, respectively, and the corresponding costs were $142,300 and $633,900, resulting in an incremental costeffectiveness ratio of $473,400/quality-adjusted life year gained. The results were most sensitive to the cost of OCA. Conclusion: OCA is a promising new therapy to substantially improve the long-term outcomes of PBC patients, but at its current annual price of $69,350, it is not cost-effective using a willingness-to-pay threshold of $100,000/quality-adjusted life year; pricing below $18,450/year is needed to make OCA cost-effective. (HEPATOLOGY 2017;65:920-928).
P rimary biliary cholangitis (PBC) is a rare, chronic, progressive autoimmune liver disease that mainly affects middle-aged women. (1) In the United States, up to 130,000 individuals are estimated to have PBC. (2, 3) It is one of the top six indications for liver transplantation and accounts for 5% of all liver transplants. (2, 4, 5) Among patients who are diagnosed with relatively advanced disease, median survival is estimated to range 6-10 years without liver transplantation. (6) Though hepatocellular carcinoma (HCC) is a rare disease in PBC patients, i.e., 3.4 cases/1,000 patient-years, it can still be a critical consequence of the disease, especially in male patients who do not respond adequately to ursodeoxycholic acid (UDCA).
On a biochemical level, PBC can be divided into early-stage disease with normal albumin and normal total bilirubin, moderately advanced disease with either low albumin or high total bilirubin, and advanced disease with both low albumin and high total bilirubin. (8) Alkaline phosphatase (ALP) and bilirubin levels are Abbreviations: ALP, alkaline phosphatase; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; OCA, obeticholic acid; PBC, primary biliary cholangitis; POISE, The PBC OCA International Study of Efficacy; QALY, quality-adjusted life year; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
significant predictors of risk for death and liver transplant in PBC patients. (9) Lifetime treatment is recommended for all patients with PBC. Until recently, UDCA was the only medication available for treatment of PBC. Patients with early-stage disease treated with UDCA have an overall survival similar to the general population. For patients with moderate to severe disease, UDCA treatment significantly improves average time to requirement for liver transplantation. (10) However, around 40% of patients with PBC do not achieve adequate improvement in biochemical measures of liver function while undergoing UDCA treatment. (6) Obeticholic acid (OCA), recently approved by the Food and Drug Administration, is a novel bile acid analogue that has shown positive effects on biochemical markers of liver function in the 1-year double-blind phase 3 PBC OCA International Study of Efficacy (POISE) trial. (11) OCA represents a significant advance in treatment for PBC patients who had an inadequate response to UDCA. However, the POISE trial provides only 12 months of study, and no long-term clinical effectiveness data are yet available. In addition, the list price of OCA, i.e., nearly $70,000/year, is substantially higher than that of the previous standard of care, UDCA, which costs around $3,000/year; and its costeffectiveness for PBC treatment is unknown. Therefore, the primary aim of our study was to estimate the longterm clinical outcomes and cost-effectiveness of OCA treatment for patients with PBC who have inadequate response to UDCA monotherapy.
Materials and Methods

MODEL OVERVIEW
We developed a microsimulation model (individuallevel state transition model) that simulated long-term outcomes of PBC in patients treated with UDCA monotherapy versus OCA plus UDCA. The patient characteristics of the simulated cohort matched the baseline characteristics in the phase 3 POISE trial. (11) In the model, patients progressed through different health states of the natural history of PBC that included PBC stages 1-3, as defined by the Ludwig scoring system, (12) compensated cirrhosis, decompensated cirrhosis, HCC, and liver transplant (Fig. 1) . For each treatment strategy, we estimated the incidence of advanced stages of liver disease, mortality, expected life years, quality-adjusted life years (QALYs), and health care costs. We simulated 1 million patients in the model to account for first-order uncertainty.
BASELINE POPULATION
The baseline population in our model was adults with PBC who were not adequately responding to UDCA monotherapy. Patient demographic characteristics of the simulated cohort were selected such that the patients in the model matched the patients in the POISE study. (11) The mean age of patients was 55.8 years, and 91% were female. At baseline, 90% of the patients had PBC stages 1-3 and 10% had compensated cirrhosis (Supporting Table S1 ).
TREATMENT STRATEGIES
We simulated two treatment strategies: UDCA monotherapy and OCA plus UDCA. Patients having PBC stages 1-3 and compensated cirrhosis were treated for PBC. For the OCA plus UDCA arm, we used data from the titration arm of the POISE study, in which patients initiated treatment at 5 mg once daily and increased to 10 mg if they tolerated treatment and had not yet achieved the primary composite endpoint, which was defined as having normal bilirubin, and ALP <1.67 3 upper limit of normal (ULN) with an ALP reduction of at least 15%.
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TREATMENT RESPONSE
We divided patients into four categories based on their response to treatment as measured by bilirubin level and ALP reduction after 12 months of treatment: normal bilirubin and ALP <1.673ULN, normal bilirubin and ALP 1.673ULN, abnormal bilirubin and ALP <1.673ULN, and abnormal bilirubin and ALP 1.673ULN (Table 1) . We adjusted disease progression according to these response categories. In particular, after 12 months of treatment, we simulated the progression of PBC disease based on patients' response. Patients with normal bilirubin and ALP <1.673ULN had the slowest disease progression, while patients with abnormal bilirubin and ALP 1.673ULN had the fastest progression. We assumed that treatment effects persisted after 12 months. In other words, if a patient had abnormal bilirubin and ALP 1.673ULN at the end of 12 months, the patient's disease continued to progress at the same rate. We assumed that the OCA plus UDCA treatment was not effective in patients who did not meet the primary composite endpoint and would therefore stop the treatment. Patients also stopped the treatment in the model if they progressed to decompensated cirrhosis despite the achievement of the primary endpoint.
PBC NATURAL HISTORY
The natural history of PBC was defined using PBC stages 1-3, as defined by the Ludwig scoring system, (12) FIG. 1. Model structure for the natural history of PBC. Each rectangle represents patients' health state, and arrows represent potential transitions from one state to another. The oval represents the possibility of experiencing pruritus during the first year of treatment. The model simulated two treatment strategies: (1) UDCA treatment and (2) OCA plus UDCA treatment. Patients were provided treatment in PBC stages 1-3 or in compensated cirrhosis. Patients continued treatment until they progressed to decompensated cirrhosis or failed to achieve the primary end point as defined in the POISE study. Patients' disease continued to progress depending on the ALP reduction and bilirubin levels at the end of the first year of treatment. Patients with abnormal bilirubin and those in advanced stages of PBC were eligible for a liver transplant and had additional liver-related mortality. Because there are limited data on the natural history of PBC patients, we derived some estimates by making some clinically plausible assumptions. For early stages of PBC, we calibrated disease progression rates such that the model-predicted transplant-free survival matched with the PBC Global Study, a meta-analysis by the PBC Global Study Group, which is an international nonprofit collaboration between medical centers that was established to search for reliable surrogate endpoints for PBC (Supporting Information and Fig.  S2 ). (9) We further adjusted these progression rates based on patients' biochemical response to treatment. Patients with abnormal bilirubin had faster disease progression than those with normal bilirubin. (9) For advanced stages of PBC, we assumed that natural history was similar to that of hepatitis C because the clinical evidence suggests that the risk of developing HCC in PBC patients is similar to that in hepatitis C patients (Supporting Information). (13, 14) Our model incorporated age-specific and sex-specific background mortality based on US life tables. (15) 
ADVERSE EVENTS
Pruritus is a common symptom of PBC, and it is the primary treatment-related adverse event which can even result with discontinuation. (16, 17) It was also the most experienced side effect in POISE. (11) PBC patients in our model had pruritus during the first year of treatment, which varied in severity and was classified as mild, moderate, or severe (Supporting Table S3 ). We used the pruritus severity distribution from POISE. (18) We also incorporated the effect of pruritus management on quality of life and cost (Supporting Tables S3 and S4 ).
HEALTH-RELATED AND TREATMENT COSTS
We assumed that the cost of managing different sequelae of PBC (e.g., decompensated cirrhosis, HCC, liver transplant) was similar to the cost of managing corresponding sequelae of hepatitis C. Therefore, we used published studies of treatments for hepatitis C virus to derive health-state costs (Supporting Table   S3 ). (19) All costs were converted to a 2015 baseline using the medical care component of the Consumer Price Index. (20) For patients who had pruritus, we assumed an additional cost associated with two primary care visits in a year. (21) We also applied the cost of 1 year of pruritus treatment using recommended drugs such as cholestyramine or hydroxyzine (22) (Supporting Information). The annual cost of UDCA was $3,163, which was estimated using an average UDCA dosage and wholesale acquisition cost from Red Book. (22, 23) The annual wholesale acquisition cost of OCA of $69,350 was used in the base case.
HEALTH-RELATED UTILITIES
We assigned health-related quality-of-life utilities for each health state in our model, with 0 denoting death and 1 denoting perfect health. Health-state utilities from publicly available literature were used in the model (Supporting Table S3 ). Because PBC-specific utilities by different stages of disease were not available, we used utilities of health states for patients with hepatitis C. In particular, we used health state-specific utility weights from a published study using the EuroQol-5D instrument (24, 25) and adjusted these weights to the US population norm (Supporting Table S5 ). (26) We also applied a disutility to patients who experienced pruritus.
MODEL VALIDATION
We validated our model using data from a metaanalysis, the Global PBC Study, which provided 15-year transplant-free survival of patients with different responses to UDCA treatment (9) (Supporting Information).
MODEL OUTCOMES
We estimated the cumulative incidences of decompensated cirrhosis and HCC, the number of liver transplants and liver-related deaths, total costs, QALY, and the incremental cost-effectiveness ratio (ICER). All future costs and QALYs were discounted at 3% per year. We also applied within-cycle correction using Simpson's one-third rule. (27) 
SENSITIVITY ANALYSIS
We performed one-way sensitivity analysis to estimate the impact of varying input parameters including transition probabilities, utilities, and costs on the ICER. We also performed probabilistic sensitivity analysis using 1,000 second-order and 1 million firstorder samples that simultaneously considered uncertainty in all key model inputs. To conduct probabilistic sensitivity analysis, we used recommended statistical distributions (Supporting Table S3 ). We also estimated 95% confidence intervals of the cumulative incidences of clinical outcomes and transplant-free survival.
Results
MODEL VALIDATION
We first validated our model's natural history by stratifying long-term outcomes based on total bilirubin and ALP levels (Supporting Information). For each treatment response category, we compared the predicted 15-year transplant-free survival from the model with the values reported by the Global PBC study (Fig. 2) . Our model's predicted transplant-free survival matched reasonably well with the observed outcomes from the study (Supporting Fig. S2 ).
CLINICAL OUTCOMES
We found that in patients who had an inadequate response to UDCA, treatment with OCA would decrease 15-year cumulative incidences of decompensated cirrhosis from 12.2% to 4.5% and HCC from 9.1% to 4.0% and the cumulative number of liver transplants from 4.5% to 1.2% and liver-related deaths from 16.2% to 5.7% (Fig. 3) . In addition, treatment with OCA would increase 15-year transplant-free survival from 61.1% to 72.9% (Fig. 4) . Compared with the UDCA strategy, treating 10,000 patients using OCA plus UDCA could prevent 770 cases of decompensated cirrhosis, 510 cases of HCC, 330 liver transplants, and 1,050 liver-related deaths.
LIFETIME TREATMENT COST
The lifetime treatment cost of PBC increased from $63,100 to $902,200 with the addition of OCA to UDCA, an increment of 1,330%.
COST-EFFECTIVENESS RESULTS
The undiscounted average life years per patient treated with UDCA versus OCA plus UDCA were 19.97 and 22.23, respectively (an increment of 2.26 years). The corresponding average discounted QALYs were 10.74 to 11.78 (an increment of 1.04 years). The average discounted cost per patient in UDCA and OCA plus UDCA strategies were $142,300 and $633,900, respectively (an increment of $491,400). The ICER of OCA in comparison with UDCA was $473,400 per QALY (Table 2) . Using a willingnessto-pay threshold of $100,000/QALY, OCA was not a cost-effective option in PBC patients who have an inadequate response to UDCA monotherapy.
In addition to the analysis at the population level, we conducted a subgroup analysis by the stage of liver disease. For cirrhosis patients the ICER of OCA plus UDCA was $374,672, and for PBC patients at early stages (PBC stages 1-3) the ICER was $488,117 (Supporting Information). Although treating cirrhosis patients was not cost-effective, it was less costly and more beneficial than treating early-stage PBC patients.
FIG. 3.
Cumulative incidence of advanced stages of PBC in patients treated with UDCA versus OCA plus UDCA. Shaded region represents the 95% confidence intervals generated from the probabilistic sensitivity analysis. Cumulative incidences of (A) decompensated cirrhosis, (B) HCC, (C) liver transplants, and (D) liver-related deaths.
We also conducted a price threshold analysis to determine the price of OCA below which it becomes cost-effective, using three different willingness-to-pay thresholds. We found that OCA would meet the costeffectiveness thresholds of $50,000, $100,000, and $150,000/QALY if priced below $11,630, $18,445, and $25,260/year, respectively.
SENSITIVITY ANALYSIS
In deterministic sensitivity analysis, i.e., one-way sensitivity analysis, by changing the value of each parameter to its upper/lower value, we examined the impact of this parameter on the model outcome, i.e., ICER. We identified the 15 most sensitive model parameters, which are presented in a tornado diagram (Fig. 5) . ICER was the most sensitive to the cost of OCA, which means that the ICER value changed the most in response to the variation in the cost of OCA. Age of the patient was the second most sensitive parameter. The probabilistic sensitivity analysis results were presented as a cost-effectiveness acceptability curve (Fig. 6) . Using a willingness-to-pay threshold of $100,000/QALY, we found that the probability of cost-effectiveness of OCA was 0, i.e., never costeffective, at this threshold.
Discussion
OCA represents a major advancement in the treatment of PBC patients who have an inadequate response to UDCA. In our analysis, we estimated the long-term effectiveness and cost-effectiveness of OCA plus UDCA in comparison with UDCA monotherapy. Our study showed that OCA, as a second-line treatment, is expected to result in significant clinical benefit *Results correspond to inadequate response to UDCA, as observed in the POISE study.
FIG. 4.
Transplant-free survival in PBC patients who had inadequate response to UDCA monotherapy. Shaded region represents the 95% confidence intervals generated from the probabilistic sensitivity analysis.
by substantially increasing transplant-free survival and decreasing the incidence of decompensated cirrhosis, HCC, liver-related deaths, and need for liver transplantation in PBC patients. However, at its current price, treatment with OCA is not cost-effective using a commonly cited cost-effectiveness threshold. Our analysis estimates the cost-effectiveness and long-term impact of OCA for the treatment of patients with PBC. Published clinical studies have only provided short-term outcomes of OCA in PBC patients. (23, 28) By developing a comprehensive and clinically valid simulation model, our study aimed to predict long-term clinical outcomes including decompensated cirrhosis, HCC, and need for liver transplant in PBC patients treated with OCA. In addition, we evaluated the cost of treatment of OCA and any resulting cost offsets because of reduction in advanced outcomes of PBC. Earlier modeling studies have only evaluated the long-term outcomes of UDCA treatment. (29) (30) (31) As with any model, ours has limitations. A key limitation is the lack of data to inform the natural history of PBC. For this reason, we calibrated the model to match hard clinical endpoints including the 15-year transplant-free survival stratified by different ALP and bilirubin levels. Second, our model draws on hepatitis C data to inform cost and quality-of-life parameters because of the lack of economic and quality-of-life data in PBC patients. However, sensitivity analysis on these parameters demonstrated that model outcomes were robust to uncertainty surrounding these inputs. Third, because there are currently no data on the longterm efficacy of OCA, we made the simplifying assumption that the treatment effects persisted or remained unchanged after 12 months. Our assumption could have overestimated the clinical benefits of OCA and therefore underestimated the incremental costeffectiveness ratio. In other words, OCA may be even less cost-effective than we determined in our analysis. As long-term outcomes associated with OCA use in PBC patients become available to us, we will be able to reanalyze our model and update the results. Fourth, we did not incorporate patients who are intolerant to UDCA in our model. Because the prevalence of UDCA intolerance is very low, (32) we believe that it would not have a significant impact on the model outcomes. Finally, we did not consider retreatment of patients who failed to achieve the primary endpoint because there are no data to inform the appropriate treatment of these patients.
The rising cost of health care management has raised concerns regarding the affordability and budget impact of costly treatments. For example, recent experience from the availability of highly effective yet expensive treatments for hepatitis C virus show that the high prices of therapeutic agents could restrict their availability and affect patient and public health outcomes. Assessing the value of drugs or the value-based pricing of drugs can help achieve optimal outcomes at the population level. Though PBC is a rare disease, the average lifetime cost of PBC treatment could increase by 1,330% from $63,000 to $902,000. Furthermore, manufacturers do not typically give discounts to private insurers on orphan drugs, which could increase the burden on insurers as well as patients.
The assessment of whether a PBC drug or any treatment is cost-effective depends on the willingness-topay threshold being used. Some have argued that the willingness-to-pay threshold should not be uniform but should factor in disease prevalence within the population, i.e., lower thresholds for treatment of common diseases and higher thresholds for treatment of rare diseases. (33) From our analysis, we found that even when considering a higher cost-effectiveness threshold of $250,000, OCA was still not cost-effective at its current list price.
We do not recommend that clinicians should choose less effective management strategies because of its lower price; instead, we propose that the price of PBC treatment needs to be reduced such that the treatment becomes cost-effective and more affordable. We also anticipate that in the near future several new treatment options will become available for PBC treatment, (1) (2) (3) which could bring down the drug prices because of competition, as seen in hepatitis. (4, 5) In conclusion, we present the results of a comprehensive simulation modeling analysis evaluating the clinical and cost-effectiveness of OCA treatment in PBC patients who have an inadequate response to UDCA. Our analysis projects that the use of OCA will substantially improve long-term clinical outcomes of PBC patients. However, substantial price reduction (below $18,450/year, a 73% reduction from the list price) is needed to make treatment with OCA costeffective in PBC patients.
